Armata Pharmaceuticals, Inc. (ARMP)
USD 1.12
(16.67%)
USD 1.12
(16.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -40.89 Million USD | -10.68% |
| 2022 | -36.94 Million USD | -55.09% |
| 2021 | -23.82 Million USD | -10.35% |
| 2020 | -21.58 Million USD | -9.29% |
| 2019 | -19.75 Million USD | -57.71% |
| 2018 | -12.52 Million USD | 22.48% |
| 2017 | -16.15 Million USD | 30.89% |
| 2016 | -23.37 Million USD | -128.59% |
| 2015 | -10.22 Million USD | 27.52% |
| 2014 | -14.11 Million USD | 5.85% |
| 2013 | -14.98 Million USD | -272.42% |
| 2012 | -4.02 Million USD | 0.0% |
| 2008 | -21.16 Million USD | -27.87% |
| 2007 | -16.55 Million USD | 54.93% |
| 2006 | -36.72 Million USD | -89.84% |
| 2005 | -19.34 Million USD | -27.53% |
| 2004 | -15.17 Million USD | -9.9% |
| 2003 | -13.8 Million USD | 39.3% |
| 2002 | -22.74 Million USD | 20.5% |
| 2001 | -28.6 Million USD | -86.92% |
| 2000 | -15.3 Million USD | -37.86% |
| 1999 | -11.1 Million USD | -21.98% |
| 1998 | -9.1 Million USD | 38.93% |
| 1997 | -14.9 Million USD | -23.14% |
| 1996 | -12.1 Million USD | -16.35% |
| 1995 | -10.4 Million USD | -25.3% |
| 1994 | -8.3 Million USD | -53.7% |
| 1993 | -5.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.22 Million USD | -6.78% |
| 2024 Q2 | -11.91 Million USD | -16.48% |
| 2023 FY | -40.89 Million USD | -10.68% |
| 2023 Q1 | -11.34 Million USD | -9.85% |
| 2023 Q2 | -9.62 Million USD | 15.13% |
| 2023 Q4 | -9.57 Million USD | 7.32% |
| 2023 Q3 | -10.33 Million USD | -7.34% |
| 2022 Q2 | -9.22 Million USD | -5.07% |
| 2022 FY | -36.94 Million USD | -55.09% |
| 2022 Q1 | -8.77 Million USD | -45.09% |
| 2022 Q4 | -10.32 Million USD | -19.78% |
| 2022 Q3 | -8.62 Million USD | 6.48% |
| 2021 Q3 | -6.14 Million USD | 0.86% |
| 2021 Q4 | -6.04 Million USD | 1.55% |
| 2021 Q1 | -5.43 Million USD | 15.78% |
| 2021 Q2 | -6.19 Million USD | -14.0% |
| 2021 FY | -23.82 Million USD | -10.35% |
| 2020 Q2 | -4.59 Million USD | 6.73% |
| 2020 Q3 | -5.62 Million USD | -22.51% |
| 2020 Q4 | -6.45 Million USD | -14.76% |
| 2020 FY | -21.58 Million USD | -9.29% |
| 2020 Q1 | -4.92 Million USD | -12.45% |
| 2019 Q1 | -3.6 Million USD | 24.56% |
| 2019 FY | -19.75 Million USD | -57.71% |
| 2019 Q2 | -5.15 Million USD | -43.04% |
| 2019 Q3 | -6.77 Million USD | -31.39% |
| 2019 Q4 | -4.37 Million USD | 35.43% |
| 2018 Q2 | -3.05 Million USD | 0.1% |
| 2018 FY | -12.52 Million USD | 22.48% |
| 2018 Q4 | -4.78 Million USD | -192.0% |
| 2018 Q3 | -1.63 Million USD | 46.36% |
| 2018 Q1 | -3.05 Million USD | -29.18% |
| 2017 Q2 | -9.68 Million USD | -188.36% |
| 2017 Q4 | -2.36 Million USD | -217.02% |
| 2017 Q1 | -3.35 Million USD | 71.69% |
| 2017 FY | -16.15 Million USD | 30.89% |
| 2017 Q3 | -746 Thousand USD | 92.3% |
| 2016 Q1 | -4.51 Million USD | -53.67% |
| 2016 FY | -23.37 Million USD | -128.59% |
| 2016 Q3 | -3.4 Million USD | 5.07% |
| 2016 Q4 | -11.86 Million USD | -248.22% |
| 2016 Q2 | -3.58 Million USD | 20.56% |
| 2015 Q3 | -2.42 Million USD | 6.33% |
| 2015 Q2 | -2.59 Million USD | -14.34% |
| 2015 Q1 | -2.26 Million USD | 20.34% |
| 2015 FY | -10.22 Million USD | 27.52% |
| 2015 Q4 | -2.94 Million USD | -21.09% |
| 2014 Q2 | -3.71 Million USD | -43.74% |
| 2014 Q3 | -4.94 Million USD | -33.06% |
| 2014 Q4 | -2.84 Million USD | 42.46% |
| 2014 FY | -14.11 Million USD | 5.85% |
| 2014 Q1 | -2.58 Million USD | 50.15% |
| 2013 Q3 | -2.34 Million USD | 61.77% |
| 2013 Q4 | -5.18 Million USD | -121.61% |
| 2013 Q2 | -6.12 Million USD | -359.41% |
| 2013 Q1 | -1.33 Million USD | 0.0% |
| 2013 FY | -14.98 Million USD | -272.42% |
| 2012 FY | -4.02 Million USD | 0.0% |
| 2009 Q1 | -1.79 Million USD | 83.52% |
| 2009 Q2 | 7.3 Million USD | 507.36% |
| 2009 Q3 | 729 Thousand USD | -90.02% |
| 2008 Q3 | -2.87 Million USD | 25.84% |
| 2008 FY | -21.16 Million USD | -27.87% |
| 2008 Q4 | -10.88 Million USD | -279.41% |
| 2008 Q1 | -3.53 Million USD | 31.91% |
| 2008 Q2 | -3.87 Million USD | -9.38% |
| 2007 Q1 | -33.77 Million USD | -1750.47% |
| 2007 Q2 | -4.27 Million USD | 87.33% |
| 2007 Q3 | -3.3 Million USD | 22.69% |
| 2007 Q4 | -5.19 Million USD | -57.07% |
| 2007 FY | -16.55 Million USD | 54.93% |
| 2006 Q1 | -3.77 Million USD | -1.45% |
| 2006 Q2 | -27.92 Million USD | -640.66% |
| 2006 Q4 | -1.82 Million USD | 43.16% |
| 2006 Q3 | -3.21 Million USD | 88.5% |
| 2006 FY | -36.72 Million USD | -89.84% |
| 2005 Q2 | -5.12 Million USD | -10.38% |
| 2005 FY | -19.34 Million USD | -27.53% |
| 2005 Q3 | -5.86 Million USD | -14.4% |
| 2005 Q1 | -4.64 Million USD | -109.43% |
| 2005 Q4 | -3.71 Million USD | 36.62% |
| 2004 Q3 | -3.73 Million USD | 14.17% |
| 2004 Q4 | -2.21 Million USD | 40.67% |
| 2004 Q1 | -4.86 Million USD | 21.85% |
| 2004 Q2 | -4.35 Million USD | 10.45% |
| 2004 FY | -15.17 Million USD | -9.9% |
| 2003 Q2 | -6.61 Million USD | -1171.35% |
| 2003 Q4 | -6.22 Million USD | -1276.33% |
| 2003 FY | -13.8 Million USD | 39.3% |
| 2003 Q1 | -520 Thousand USD | 90.93% |
| 2003 Q3 | -452 Thousand USD | 93.16% |
| 2002 FY | -22.74 Million USD | 20.5% |
| 2002 Q1 | -6.22 Million USD | 42.71% |
| 2002 Q2 | -6.27 Million USD | -0.72% |
| 2002 Q3 | -4.51 Million USD | 28.07% |
| 2002 Q4 | -5.73 Million USD | -27.09% |
| 2001 Q3 | 11.88 Million USD | 326.03% |
| 2001 Q4 | -10.86 Million USD | -191.44% |
| 2001 Q2 | -5.25 Million USD | 14.26% |
| 2001 Q1 | -6.13 Million USD | 34.37% |
| 2001 FY | -28.6 Million USD | -86.92% |
| 2000 Q3 | 567.53 Thousand USD | 114.64% |
| 2000 FY | -15.3 Million USD | -37.86% |
| 2000 Q4 | -9.34 Million USD | -1746.3% |
| 2000 Q2 | -3.87 Million USD | -46.32% |
| 2000 Q1 | -2.64 Million USD | -431.22% |
| 1999 FY | -11.1 Million USD | -21.98% |
| 1999 Q1 | -2.7 Million USD | -268.75% |
| 1999 Q2 | -2.7 Million USD | 0.0% |
| 1999 Q3 | -3.2 Million USD | -18.52% |
| 1999 Q4 | 800 Thousand USD | 125.0% |
| 1998 Q2 | -3.1 Million USD | 16.22% |
| 1998 Q4 | 1.6 Million USD | 148.48% |
| 1998 Q3 | -3.3 Million USD | -6.45% |
| 1998 Q1 | -3.7 Million USD | 9.76% |
| 1998 FY | -9.1 Million USD | 38.93% |
| 1997 Q3 | -3 Million USD | 16.67% |
| 1997 Q1 | -3.5 Million USD | -40.0% |
| 1997 FY | -14.9 Million USD | -23.14% |
| 1997 Q4 | -4.1 Million USD | -36.67% |
| 1997 Q2 | -3.6 Million USD | -2.86% |
| 1996 FY | -12.1 Million USD | -16.35% |
| 1996 Q4 | -2.5 Million USD | 30.56% |
| 1996 Q3 | -3.6 Million USD | -24.14% |
| 1996 Q1 | -2.8 Million USD | 3.45% |
| 1996 Q2 | -2.9 Million USD | -3.57% |
| 1995 Q3 | -2.2 Million USD | 8.33% |
| 1995 Q4 | -2.9 Million USD | -31.82% |
| 1995 FY | -10.4 Million USD | -25.3% |
| 1995 Q1 | -2.6 Million USD | -18.18% |
| 1995 Q2 | -2.4 Million USD | 7.69% |
| 1994 Q4 | -2.2 Million USD | 0.0% |
| 1994 FY | -8.3 Million USD | -53.7% |
| 1994 Q1 | 100 Thousand USD | 101.82% |
| 1994 Q2 | -2.1 Million USD | -2200.0% |
| 1994 Q3 | -2.2 Million USD | -4.76% |
| 1993 Q4 | -5.5 Million USD | -5600.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | -5.4 Million USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | -28.118% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -329.607% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 21.244% |
| Azitra, Inc. | -7.61 Million USD | -436.868% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -398.963% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -495.866% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | -41.039% |
| CEL-SCI Corporation | -31.47 Million USD | -29.908% |
| iBio, Inc. | -16.63 Million USD | -145.822% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -65.326% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -102.602% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -72.053% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -191.013% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -717.31% |
| NanoViricides, Inc. | -8.51 Million USD | -380.149% |
| Oragenics, Inc. | -20.9 Million USD | -95.6% |
| BiomX Inc. | -27.68 Million USD | -47.697% |
| BiomX Inc. | -27.68 Million USD | -47.697% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 490.918% |
| Palatin Technologies, Inc. | -22.49 Million USD | -81.765% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 2.717% |
| Theriva Biologics, Inc. | -21.43 Million USD | -90.798% |